 |
1 Disease |  |
0 Trials |
|
0 Trials |  |
92 News |  |
| «12 |
- rivipansel (GMI-1070) / GlycoMimetics
Trial primary completion date: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects (clinicaltrials.gov) - Feb 5, 2015
P1, N=15, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Jan 2015 --> Sep 2015
- ||||| rivipansel (GMI-1070) / Glycomimetics
Trial initiation date: RESET: Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease (clinicaltrials.gov) - Jan 15, 2015
P3, N=350, Not yet recruiting, Sponsor: Pfizer
Trial primary completion date: Jan 2015 --> Sep 2015 Initiation date: Nov 2014 --> Jun 2015
- rivipansel (GMI-1070) / GlycoMimetics
Enrollment closed: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects (clinicaltrials.gov) - Dec 24, 2014
P1, N=15, Active, not recruiting, Sponsor: Pfizer
Initiation date: Nov 2014 --> Jun 2015 Not yet recruiting --> Active, not recruiting
- |||| rivipansel (GMI-1070) / Glycomimetics
Trial primary completion date: RESET: Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease (clinicaltrials.gov) - Dec 19, 2014
P3, N=350, Not yet recruiting, Sponsor: Pfizer
Not yet recruiting --> Active, not recruiting Trial primary completion date: Feb 2018 --> Jul 2018
- |||| rivipansel (GMI-1070) / Glycomimetics
Trial primary completion date: RESET: Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease (clinicaltrials.gov) - Oct 30, 2014
P3, N=350, Not yet recruiting, Sponsor: Pfizer
Trial primary completion date: Feb 2018 --> Jul 2018 Trial primary completion date: Nov 2017 --> Feb 2018
- | rivipansel (GMI-1070) / Glycomimetics
Trial completion: A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects (clinicaltrials.gov) - Sep 5, 2014
P1, N=48, Completed, Sponsor: Pfizer
Trial primary completion date: Nov 2017 --> Feb 2018 Active, not recruiting --> Completed
- | rivipansel (GMI-1070) / GlycoMimetics
New P1 trial: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects (clinicaltrials.gov) - Aug 15, 2014
P1, N=15, Not yet recruiting, Sponsor: Pfizer
- rivipansel (GMI-1070) / Glycomimetics
Enrollment closed: A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects (clinicaltrials.gov) - Aug 15, 2014
P1, N=42, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- rivipansel (GMI-1070) / Glycomimetics
Enrollment open: A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects (clinicaltrials.gov) - Jul 17, 2014
P1, N=42, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- |||||||||| rivipansel (GMI-1070) / Glycomimetics
New P3 trial: RESET: Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease (clinicaltrials.gov) - Jul 12, 2014
P3, N=350, Not yet recruiting, Sponsor: Pfizer
- rivipansel (GMI-1070) / Glycomimetics
Enrollment closed: A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects (clinicaltrials.gov) - Jan 30, 2014
P1, N=42, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Recruiting Suspended --> Active, not recruiting
- |||| rivipansel (GMI-1070) / Glycomimetics
Trial completion: Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis (clinicaltrials.gov) - Dec 15, 2013
P2, N=76, Completed, Sponsor: Pfizer
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- | rivipansel (GMI-1070) / Glycomimetics
New P1 trial: A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects (clinicaltrials.gov) - Sep 11, 2013
P1, N=42, Active, not recruiting, Sponsor: Pfizer
- rivipansel (GMI-1070) / Glycomimetics
Enrollment change: Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease (clinicaltrials.gov) - Feb 29, 2012
P1/2, N=15, Completed, Sponsor: GlycoMimetics Incorporated
Active, not recruiting --> Completed N=20 --> 15